Hasan, Shemonti
Zorio, Onilia
Keegan, B. Mark
Weinshenker, Brian G.
Flanagan, Eoin P.
Tobin, W. Oliver
Kantarci, Orhun H.
Toledano, Michel
Pittock, Sean J.
Lopez-Chiriboga, Sebastian
Zekeridou, Anastasia
Valencia-Sanchez, Cristina http://orcid.org/0000-0003-0116-8035
Article History
Received: 5 June 2023
Revised: 2 August 2023
Accepted: 3 August 2023
First Online: 19 August 2023
Declarations
:
: S. Hasan, O. Zorio, O.H. Kantarci, M. Toledano, and C. Valencia-Sanchez declare that they have no conflict of interest. B.M. Keegan is funded by the Applebaum Family and is a member of the Center for Multiple Sclerosis and Autoimmune Research Mayo Clinic, receives publishing royalties for Common Pitfalls in Multiple Sclerosis and CNS Demyelinating Diseases, and is an Editorial Board member of Multiple Sclerosis and Related Disorders. B.G. Weinshenker reports consulting fees from CANbridge Pharmaceuticals, Horizon Pharmaceuticals, Roche/Genentech, and speaking fees from Mitsubishi Tanabe and Horizon Pharmaceuticals. He reports payment from MedImmune/VielaBio/Horizon for participation in the NMOSD adjudication committee for the inebilizumab clinical trial and from Alexion for participation in the NMOSD adjudication committee for the eculizumab clinical trial. He reports payment from UCB Biosciences for participation in the MOG-IgG associated disorders clinical trial adjudication committee. He received travel support from Mitsubishi Tanabe. He has a patent NMO-IgG for diagnosis of neuromyelitis optica with royalties received from RSR Ltd, Oxford University, and Hospices Civils de Lyon. E.P. Flanagan has served on advisory boards for Alexion, Genentech, UCB, and Horizon Therapeutics outside the submitted work; has a patent for DACH1-IgG as a biomarker of paraneoplastic autoimmunity pending; has received speaker honoraria from Pharmacy Times; has received royalties from UpToDate; was a site primary investigator in a randomized clinical trial on inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics; has received funding from the National Institutes of Health (Grant R01NS113828); is a member of the medical advisory board of the MOG project; and is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. W.O. Tobin has received research funding from Mallinckrodt Inc, the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, and the National Institutes of Health (Grant R01NS113803 and R01NS121928) outside the submitted work. He has received honoraria from Neurology Live and has co-edited Mayo Clinic Cases in Neuroimmunology. S.J. Pittock reported grants, personal fees, and nonfinancial support from Alexion and MedImmune/Viela Bio/Horizon (all compensation is paid directly to the Mayo Clinic); grants from the National Institutes of Health, Grifols, NovelMed, and F. Hoffmann-LaRoche/Roche/Genentech (all compensation is paid directly to Mayo Clinic); consulting for Astellas (compensation to Mayo Clinic and personal compensation); personal fees from Sage Therapeutics, UCB, and F. Hoffmann-LaRoche/Roche/Genentech; and had patent #8,889,102 issued, patent #9,891,219B2 issued, and a patent for GFAP-IgG; Septin-5-IgG; MAP1B-IgG; Kelch-like protein 11; PDE10A pending. A.S. Lopez-Chiriboga has served on advisory boards for Genentech and Horizon Therapeutics. A. Zekeridou reported grants from Roche/Genentech outside the submitted work and has a patent for DACH1-IgG as biomarker of neurological autoimmunity pending and a patent for PDE10A-IgG as biomarker of neurological autoimmunity pending.
: This research study was conducted retrospectively from data obtained for clinical purposes. This study was approved by the Mayo Clinic Institutional Review Board. All patients signed a consent to use their medical records for research.